Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ramon Matawaran

Internal Medicine Norfolk, VA Medical Doctor

NPI 1467427773 CMS profile 65836

171 Kempsville Rd Bldg A, Norfolk, VA 23502

Open in the dashboard

General payments

$6,478

330 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ramon Matawaran of Norfolk, VA is reported in the CMS Open Payments database as having received $6,478 across 330 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $393 20
2024 General $708 33
2023 General $1,845 81
2022 General $1,224 62
2021 General $1,070 59
2020 General $253 16
2019 General $985 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ramon Matawaran
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ramon Matawaran were reported at $393. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ramon Matawaran Internal Medicine median Middle half National median
2019 $985 $159 $48–$570 $163
2020 $253 $119 $33–$402 $114
2021 $1,070 $135 $37–$521 $132
2022 $1,224 $141 $42–$496 $149
2023 $1,845 $149 $45–$519 $160
2024 $708 $154 $47–$537 $164
2025 $393 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $958 26 payments
  2. AstraZeneca Pharmaceuticals LP $825 42 payments
  3. Lilly USA, LLC $797 37 payments
  4. Novo Nordisk Inc $416 23 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $414 37 payments
  6. Pfizer Inc. $400 27 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $322 20 payments
  8. Novartis Pharmaceuticals Corporation $206 14 payments
  9. Corcept Therapeutics $202 12 payments
  10. AbbVie, Inc. $190 10 payments
  11. Other $1,748 82 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,470 329 payments
  2. Education $8 1 payment
Products named General payments · program years 2019–2025
  1. Repatha $803 23 payments
  2. FARXIGA $549 28 payments
  3. XIFAXAN $414 37 payments
  4. MOUNJARO $395 12 payments
  5. Otezla $395 15 payments
  6. Ozempic $361 19 payments
  7. TRULICITY $272 18 payments
  8. JARDIANCE Diabetes $236 16 payments
  9. JARDIANCE Diabetes $220 14 payments
  10. Korlym $202 12 payments
  11. Other $4,263 253 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 97 drugs

Part D claims

4,376

Median for Internal Medicine: 777

Drug cost

$395,044

Median for Internal Medicine: $73,373

Branded share of claims

16.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 62 $64,439
Farxiga Dapagliflozin Propanediol Brand 38 $50,976
Trulicity Dulaglutide Brand 38 $48,520
Mounjaro Tirzepatide Brand 33 $45,823
Jardiance Empagliflozin Brand 32 $41,630
Eliquis Apixaban Brand 40 $41,168
Repatha Sureclick Evolocumab Brand 28 $24,203
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 23 $17,103
Xarelto Rivaroxaban Brand 15 $13,072
Ezetimibe Generic 93 $3,111

The 10 drugs with the highest cost, of 97 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$92,391

Of which drugs: $1,741

Medicare patients

321

Average age 75

Services billed

1,396

151 women, 170 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 32%
Ischemic heart disease 31%
Osteoporosis 21%
Atrial fibrillation 18%
Chronic kidney disease 15%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $178
$178 28 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $86
$86 32 —
Sunosi
  • Axsome Therapeutics, Inc. $56
$56 — —
Otezla
  • Amgen Inc. $47
$47 — —
AMYVID
  • Lilly USA, LLC $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

330 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record